# Yuanmei Zhu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4557427/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 28 papers | 749 citations | 567281 15 h-index | 526287 27 g-index |
| 28 all docs | 28 docs citations | 28 times ranked | 870 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. Journal of Virology, 2020, 94, . | 3.4 | 164 |
| 2 | Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition. Journal of Virology, 2017, 91, . | 3.4 | 65 |
| 3 | Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. Science Advances, 2020, 6, . | 10.3 | 57 |
| 4 | A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly PotentIn Vitro,Ex Vivo, andIn VivoAntiviral Activity. Journal of Virology, 2017, 91, . | 3.4 | 53 |
| 5 | Structural and functional characterization of HIV-1 cell fusion inhibitor T20. Aids, 2019, 33, 1-11. | 2.2 | 38 |
| 6 | A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. Journal of Virology, 2017, 91, . | 3.4 | 35 |
| 7 | Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity. Journal of Virology, 2019, 93, . | 3.4 | 34 |
| 8 | Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. Journal of Virology, 2018, 92, . | 3.4 | 30 |
| 9 | Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. PLoS Pathogens, 2019, 15, e1007552. | 4.7 | 30 |
| 10 | Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models. Journal of Virology, 2018, 92, . | 3.4 | 29 |
| 11 | Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus. Journal of Biological Chemistry, 2018, 293, 5323-5334. | 3.4 | 27 |
| 12 | Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. Cell, 2022, 185, 131-144.e18. | 28.9 | 24 |
| 13 | Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trialâ€“approved membrane fusion inhibitor. Journal of Biological Chemistry, 2018, 293, 12703-12718. | 3.4 | 20 |
| 14 | SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. Signal Transduction and Targeted Therapy, 2021, 6, 294. | 17.1 | 20 |
| 15 | Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. Emerging Microbes and Infections, 2021, 10, 1227-1240. | 6.5 | 17 |
| 16 | A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. Journal of Virology, 2019, 93, . | 3.4 | 15 |
| 17 | Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Emerging Microbes and Infections, 2021, 10, 810-821. | 6.5 | 15 |
| 18 | Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket. Frontiers in Cellular and Infection Microbiology, 2018, 8, 51. | 3.9 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Mechanism of HIV-1 Resistance to an Electronically Constrained Î±-Helical Peptide Membrane Fusion Inhibitor. Journal of Virology, 2018, 92, . | 3.4 | 12 |
| 20 | SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron. Emerging Microbes and Infections, 2022, 11, 1819-1827. | 6.5 | 10 |
| 21 | Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy. Cellular and Molecular Immunology, 2021, 18, 660-674. | 10.5 | 9 |
| 22 | The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors. Journal of Virology, 2019, 94, . | 3.4 | 7 |
| 23 | Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor. Oncotarget, 2017, 8, 63047-63063. | 1.8 | 6 |
| 24 | Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy. Emerging Microbes and Infections, 2022, 11, 30-49. | 6.5 | 5 |
| 25 | Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors. Viruses, 2019, 11, 609. | 3.3 | 4 |
| 26 | Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41. Frontiers in Cellular and Infection Microbiology, 2022, 12, . | 3.9 | 4 |
| 27 | Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques. Journal of Virology, 2020, 94, . | 3.4 | 3 |
| 28 | Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors. Viruses, 2020, 12, 326. | 3.3 | 2 |